Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "Immune privilege"-like state of the autoreactive B cells

Clinical and Experimental Rheumatology

Volumn 20, Issue 5, 2002, Pages 625-631

  Nagafuchi, Hiroko ^a   Wakisaka, Sueshige ^a   Takeba, Yuko ^a   Takeno, Mitsuhiro ^a   Sakane, Tsuyoshi ^a   Suzuki, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; B lymphocytes; Human; Lupus

Indexed keywords

BIOTIN; CORTICOSTEROID; DNA; DNA ANTIBODY; FAS LIGAND; IMMUNOGLOBULIN G; MESSENGER RNA; PREDNISONE; STREPTAVIDIN;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOBLOTTING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036709347     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. DEAN GS, TYRRELL-PRICE J, CRAWLEY E, ISENBERG DA: Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 243-51.
2. LIOSSIS SN, TSOKOS GC: Molecular aspects in the pathogenesis of human systemic lupus erythematosus. Arch Immunol Ther Exp 2000; 48: 11-19.
3. SHOENFELD Y, ALARCON-SEGOVIA D, BUSKILA D et al.: Frontiers of SLE: Review of the 5th International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999; 29: 112-30.
4. HAHN BH: Antibodies to DNA. N Engl J Med 1998; 338: 1359-68.
5. CONRAD K, TAN EM, HUMBEL RL, SHOENFELD Y: Autoantibodies-diagnostic, pathogenic and prognostic relevance. Clin Exp Rheumatol 1997; 15: 457-65.
6. RADIC MZ, COCCA BA, SEAL SN: Initiation of systemic autoimmunity and sequence specific anti-DNA autoantibodies. Crit Rev Immunol 1999; 19: 117-26.
7. WU CY, CHIOU YH, CHIU PC, HSIEH KS: Severe pulmonary hemorrhage as the initial manifestation in systemic lupus erythematosus with active nephritis. Lupus 2001; 10: 879-82.
8. MASON LJ, ISENBERG DA: Immunopathogenesis of SLE. Baillieres Clin Rheumatol 1998; 12: 385-403.
9. JU ST, PANKA DJ, CUI H et al.: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-8.
10. VAN PARIJS L, PEREZ VL, ABBAS AK: Mechanisms of peripheral T cell tolerance. Novartis Found Symp 1998; 215: 5-40.
11. ALDERSON MR, TOUGH TW, DAVIS-SMITH T et al.: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71-7.
12. RUSSELL JH, RUSH B, WEAVER C, WANG R: Mature T cells of autoimmune 1pr/1pr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993; 90: 4409-13
13. WEINTRAUB JP, GODFREY V, WOLTHUSEN PA, CHEEK RL, EISENBERG RA, COHEN PL: Immunological and pathological consequences of mutations in both Fas and Fas ligand. Cell Immunol 1998; 186: 8-17.
14. TAKAHASHI T, TANAKA M, BRANNAN CI et al.: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
15. GRIFFITH TS, BRUNNER T, FLETCHER SM, GREEN DR, FERGUSON TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
16. STUART PM, GRIFFITH TS, USUI N, PEPOSE J, YU X, FERGUSON TA: CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
17. O'CONNELL J, BENNETT MW, O'SULLIVAN GC et al.: Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998; 186: 240-6.
18. GASTMAN BR, ATARSHI Y, REICHERT TE et al.: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
19. MYSLER E, BINI P, DRAPPA J et al.: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029-34.
20. SAKATA K, SAKATA A, VELA-ROCH N et al.: Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur J Immunol 1998; 28: 2648-60.
21. GEORGESCU L, VAKKALANKA RK, ELKON KB, CROW MK: Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622-33.
22. McNALLY J, YOO DH, DRAPPA J et al: Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997; 159: 4628-36.
23. KOVACS B, LIOSSIS SN, DENNIS GJ, TSOKOS GC: Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997; 25: 213-21.
24. LORENZ HM, GRUNKE M, HIERONYMUS T et al.: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997; 40: 306-17.
25. CHENG J, ZHOU T, LIU C et al.: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
26. KNIPPING E, KRAMMER PH, ONEL KB, LEHMAN TJ, MYSLER E, ELKON KB: Levels of soluble Fas/APO-1/ CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38: 1735-7.
27. GOEL N, ULRICH DT, ST CLAIR EW, FLEMING JA, LYNCH DH, SELDIN MF: Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995; 38: 1738-43.
28. TAN EM, COHEN AS, FRIES JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
29. HARADA T, SUZUKI N, MIZUSHIMA Y, SAKANE T: Usage of a novel class of germline Ig variable region gene for cationic anti-DNA autoantibodies in human lupus nephritis and its role for the development of the disease. J Immunol 1994; 153: 4806-15.
30. BLAISON G, KUNTZ JL, PASQUALI JL: Molecular analysis of V kappa III variable regions of polyclonal rheumatoid factors during rheumatoid arthritis. Eur J Immunol 1991; 21: 1221-7.
31. SUZUKI N, ICHINO M, MIHARA S, KANEKO S, SAKANE T: Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 344-53.
32. KASHIWAKURA J, SUZUKI N, NAGAFUCHI H et al.: Txk, a nonreceptor tyrosine kinase of the Tec family, is expressed in T helper type 1 cells and regulates interferon gamma production in human T lymphocytes. J Exp Med 1999; 190: 1147-54.
33. KIENER PA, DAVIS PM, RANKIN BM et al.: Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997; 159: 1594-8.
34. HAHNE M, RENNO T, SCHROETER M et al.: Activated B cells express functional Fas ligand. Eur J Immunol 1996; 26: 721-4.
35. MULLAUER L, MOSBERGER I, CHOTT A: Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 1998; 11: 369-75.
36. SCHATTNER EJ, ELKON KB, YOO DH et al.: CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557-65.
37. SAMUELSSON A, SONNERBORG A, HEUTS N, COSTER J, CHIODI F: Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1997; 13: 1031-8.
38. TANNER JE, ALFIERI C: Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T-cell apoptosis. Blood 1999; 94: 3439-47.
39. TIAN J, ZEKZER D, HANSSEN L, LU Y, OLCOTT A, KAUFMAN DL: Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 1081-9.
40. TINHOFER I, MARSCHITZ I, KOS M et al.: Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998; 91: 4273-81.
41. LUNDY SK, BOROS DL: Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10. Infect Immun 2002; 70: 812-9.
42. NOZAWA K, KAYAGAKI N, TOKANO Y, YAGITA H, OKUMURA K, HASIMOTO H: Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-9.
43. SAKANE T, MURAKAWA Y, SUZUKI N et al.: Familial occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosus. Am J Med 1989; 86: 385-90.
44. SAKANE T, SUZUKI N, TAKADA S et al.: B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 80-87.